For oral use.
Simparica Trio should be administered at a dose of 1.2-2.4 mg/kg of sarolaner, 0.024-0.048 mg/kg moxidectin and 5-10 mg/kg of pyrantel in accordance with the following table.
Method of administration
Tablets can be administered with or without food.
Simparica Trio tablets are palatable and readily consumed by the majority of dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
Tablet strength 3 mg/0.06 mg/12.5 mg
Tablet strength 6 mg/0.12 mg/25 mg
Tablet strength 12 mg/0.24 mg/50 mg
Tablet strength 24 mg/0.48 mg/100 mg
Tablet strength 48 mg/0.96 mg/200 mg
Tablet strength 72 mg/1.44 mg/300 mg
>2.5 - 5
>5 - 10
>10 - 20
>20 - 40
>40 - 60
Appropriate combination of tablets
The treatment schedule should be based on veterinary diagnosis, the local epidemiological situation and/or the epidemiological situation of other areas the dog has visited or is going to visit. If based on veterinarian opinion re-administration(s) of the product is required, any subsequent administration(s) must follow the minimum 1 month interval schedule.
The product should only be used in dogs when treatment of ticks / fleas / mites and gastrointestinal nematodes is indicated at the same time. In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used.
Treatment of flea and tick infestations and gastrointestinal nematodes:
The veterinary medicinal product can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infections. A single treatment is efficacious for the treatment of gastrointestinal nematodes. After treatment of the nematode infections, further flea and tick treatment should be continued with a mono-active product.
Prevention of heartworm disease and angiostrongylosis:
A single administration also prevents lungworm disease (by reducing the immature adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month. When the product replaces another lungworm or heartworm preventive product, the first dose of the product should be given within a month of the last dose of the former veterinary medicinal product. In endemic areas, dogs should receive lungworm and/or heartworm preventive treatments at monthly intervals. It is recommended that heartworm prevention treatment should be continued until at least 1 month after the last exposure to mosquitoes.
Prevention of establishment of thelaziosis (adult Thelazia callipaeda eyeworm infection):
Monthly administration of the product prevents establishment of infection with adult Thelazia callipaeda eyeworm.
Treatment of demodicosis (caused by Demodex canis):
Administration of a single dose once monthly for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multifactorial disease, it is advisable to also treat any contributing, underlying conditions appropriately.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis):
Administration of a single dose at monthly intervals for two consecutive months. Further monthly administrations of the product may be required based on clinical assessment and skin scrapings.